Effect of Empagliflozin on Left Ventricular Volumes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF)

Circulation

Volumn 143, Issue 6, 2021, Pages 516-525

  Lee, Matthew M Y ^a,d   Brooksbank, Katriona J M ^a   Wetherall, Kirsty ^b   Mangion, Kenneth ^a   Roditi, Giles ^a   Campbell, Ross T ^a   Berry, Colin ^a   Chong, Victor ^e   Coyle, Liz ^a   Docherty, Kieran F ^a   Dreisbach, John G ^f   Labinjoh, Catherine ^g   Lang, Ninian N ^a   Lennie, Vera ^h   McConnachie, Alex ^b   Murphy, Clare L ⁱ   Petrie, Colin J ^a,j   Petrie, John R ^a,d   Speirits, Iain A ^k   Sourbron, Steven ^l   Welsh, Paul ^a   Woodward, Rosemary ^c   Radjenovic, Aleksandra ^a   Mark, Patrick B ^a   McMurray, John J V ^a   Jhund, Pardeep S ^a   Petrie, Mark C ^a,d   Sattar, Naveed ^a,d   more..

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c QUEEN ELIZABETH UNIVERSITY HOSPITAL   (United Kingdom)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

^e CROSSHOUSE HOSPITAL   (United Kingdom)

^f GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^g FORTH VALLEY ROYAL HOSPITAL   (United Kingdom)

^h AYR HOSPITAL   (United Kingdom)

ⁱ ROYAL ALEXANDRA HOSPITAL   (United Kingdom)

^j MONKLANDS HOSPITAL   (United Kingdom)

^k NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^l UNIVERSITY OF SHEFFIELD   (United Kingdom)

more..

Author keywords

clinical trial; diabetes mellitus; empagliflozin; heart failure; magnetic resonance imaging; myocardium; sodium glucose transporter 2 inhibitors; ventricular remodeling

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; EMPAGLIFLOZIN; PLACEBO; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

AGED; ARTICLE; BODY SURFACE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIURETIC ACTIVITY; DOUBLE BLIND PROCEDURE; FEMALE; GLYCEMIC INDEX; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE REMODELING; HUMAN; IMPAIRED GLUCOSE TOLERANCE; KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE; LEFT VENTRICULAR GLOBAL LONGITUDINAL STRAIN; LUNG ULTRASOUND SCORE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEW YORK HEART ASSOCIATION CLASS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SIX MINUTE WALK TEST; CLINICAL TRIAL; DRUG EFFECT; HEART FAILURE; HEART STROKE VOLUME; PHARMACOLOGY;

AGED; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCOSIDES; HEART FAILURE; HUMANS; MALE; PREDIABETIC STATE; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; STROKE VOLUME; VENTRICULAR REMODELING;

EID: 85097960743     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.120.052186     Document Type: Article

References (32)

1. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: A meta-analytic approach. J Am Coll Cardiol. 2010;56:392-406. doi: 10.1016/j.jacc.2010.05.011
2. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35:569-582. doi: 10.1016/s0735-1097(99)00630-0
3. Bellenger NG, Rajappan K, Rahman SL, Lahiri A, Raval U, Webster J, Murray GD, Coats AJ, Cleland JG, Pennell DJ; CHRISTMAS Study Steering Committee and Investigators. Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: A cardiovascular magnetic resonance study. Heart. 2004;90:760-764. doi: 10.1136/hrt.2003.015552
4. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR. Antiremodeling effects on the left ventricle during betablockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol. 2000;36:2072-2080. doi: 10.1016/s0735-1097(00)01006-8
5. Tardif JC, O'Meara E, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Swedberg K; SHIFT Investigators. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: Results from the SHIFT echocardiography substudy. Eur Heart J. 2011;32:2507-2515. doi: 10.1093/eurheartj/ehr311
6. Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, McCague K, Abbas CA, Rocha R, Mitchell GF, EVALUATE-HF Investigators. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: A randomized clinical trial. JAMA. 2019;322:1-10.
7. Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, Benza RL, Gottlieb SO, Kleemann TD, Rosconi F, et al; Val-HeFT Heart Failure Trial Investigators. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol. 2002;40:970-975. doi: 10.1016/s0735-1097(02)02063-6
8. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, Shelton B. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation. 1995;91:2573-2581. doi: 10.1161/01.cir.91.10.2573
9. Colucci WS, Kolias TJ, Adams KF, Armstrong WF, Ghali JK, Gottlieb SS, Greenberg B, Klibaner MI, Kukin ML, Sugg JE; REVERT Study Group. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: The REversal of Ventricular Remodeling with Toprol-XL (REVERT) trial. Circulation. 2007;116:49-56. doi: 10.1161/CIRCULATIONAHA.106.666016
10. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-1549. doi: 10.1056/NEJMoa050496
11. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlávek J, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995-2008. doi: 10.1056/NEJMoa1911303
12. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-1424. doi: 10.1056/NEJMoa2022190
13. Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Zuo F, Quan A, Farkouh ME, Fitchett DH, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: The EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. 2019;140:1693-1702. doi: 10.1161/CIRCULATIONAHA.119.042375
14. Singh JSS, Mordi IR, Vickneson K, Fathi A, Donnan PT, Mohan M, Choy AMJ, Gandy S, George J, Khan F, et al. Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: The REFORM trial. Diabetes Care. 2020;43:1356-1359. doi: 10.2337/dc19-2187
15. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure. J Am Coll Cardiol. 2000;35:1245-1255. doi: 10.1016/s0735-1097(00)00531-3
16. Demers C, McKelvie RS, Negassa A, Yusuf S; RESOLVD Pilot Study Investigators. Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure. Am Heart J. 2001;142:698-703. doi: 10.1067/mhj.2001.118468
17. Platz E, Campbell RT, Claggett B, Lewis EF, Groarke JD, Docherty KF, Lee MMY, Merz AA, Silverman M, Swamy V, et al. Lung ultrasound in acute heart failure: Prevalence of pulmonary congestion and short-and long-term outcomes. JACC Heart Fail. 2019;7:849-858. doi: 10.1016/j. jchf.2019.07.008
18. Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: Current concepts in clinical significance and assessment. JACC Cardiovasc Imaging. 2011;4:98-108. doi: 10.1016/j.jcmg.2010.10.008
19. Kang DH, Park SJ, Shin SH, Hong GR, Lee S, Kim MS, Yun SC, Song JM, Park SW, Kim JJ. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation. 2019;139:1354-1365. doi: 10.1161/CIRCULATIONAHA.118.037077
20. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 1998;135(5 pt 1):825-832. doi: 10.1016/s0002-8703(98)70041-9
21. Packer M. Cardioprotective effects of sirtuin-1 and its downstream effectors: Potential role in mediating the heart failure benefits of SGLT2 (sodium-glucose cotransporter 2) inhibitors. Circ Heart Fail. 2020;13:e007197. doi: 10.1161/CIRCHEARTFAILURE.120.007197
22. Jung IH, Park JH, Lee JA, Kim GS, Lee HY, Byun YS, Kim BO. Left Ventricular Global Longitudinal Strain as a Predictor for Left Ventricular Reverse Remodeling in Dilated Cardiomyopathy. J Cardiovasc Imaging. 2020;28:137-149. doi: 10.4250/jcvi.2019.0111
23. Petersen SE, Aung N, Sanghvi MM, Zemrak F, Fung K, Paiva JM, Francis JM, Khanji MY, Lukaschuk E, Lee AM, et al. Reference ranges for cardiac structure and function using cardiovascular magnetic resonance (CMR) in Caucasians from the UK Biobank population cohort. J Cardiovasc Magn Reson. 2017;19:18. doi: 10.1186/s12968-017-0327-9
24. Le TT, Tan RS, De Deyn M, Goh EP, Han Y, Leong BR, Cook SA, Chin CW. Cardiovascular magnetic resonance reference ranges for the heart and aorta in Chinese at 3T. J Cardiovasc Magn Reson. 2016;18:21. doi: 10.1186/s12968-016-0236-3
25. Dreisbach JG, Mathur S, Houbois CP, Oechslin E, Ross H, Hanneman K, Wintersperger BJ. Cardiovascular magnetic resonance based diagnosis of left ventricular non-compaction cardiomyopathy: Impact of cine bSSFP strain analysis. J Cardiovasc Magn Reson. 2020;22:9. doi: 10.1186/s12968-020-0599-3
26. Liu H, Wang J, Pan Y, Ge Y, Guo Z, Zhao S. Early and quantitative assessment of myocardial deformation in essential hypertension patients by using cardiovascular magnetic resonance feature tracking. Sci Rep. 2020;10:3582. doi: 10.1038/s41598-020-60537-x
27. Mewton N, Opdahl A, Choi EY, Almeida AL, Kawel N, Wu CO, Burke GL, Liu S, Liu K, Bluemke DA, et al. Left ventricular global function index by magnetic resonance imaging-a novel marker for assessment of cardiac performance for the prediction of cardiovascular events: The multiethnic study of atherosclerosis. Hypertension. 2013;61:770-778. doi: 10.1161/HYPERTENSIONAHA.111.198028
28. Eitel I, Pöss J, Jobs A, Eitel C, de Waha S, Barkhausen J, Desch S, Thiele H. Left ventricular global function index assessed by cardiovascular magnetic resonance for the prediction of cardiovascular events in ST-elevation myocardial infarction. J Cardiovasc Magn Reson. 2015;17:62. doi: 10.1186/s12968-015-0161-x
29. McComb C, Berry C. Prognostic importance of a new measure of global systolic heart function in healthy adults. Hypertension. 2013;61:762-764. doi: 10.1161/HYPERTENSIONAHA.112.199992
30. Sourbron S. plaresmedima/PMI-0.4-SUGAR: Outcomes. October 13, 2020. Accessed October 14, 2020. http://doi.org/10.5281/zenodo.4086055.
31. Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: A comprehensive review. J Cardiovasc Magn Reson. 2016;18:89. doi: 10.1186/s12968-016-0308-4
32. Romano S, Judd RM, Kim RJ, Kim HW, Klem I, Heitner JF, Shah DJ, Jue J, White BE, Indorkar R, et al. Feature-tracking global longitudinal strain predicts death in a multicenter population of patients with ischemic and nonischemic dilated cardiomyopathy incremental to ejection fraction and late gadolinium enhancement. JACC Cardiovasc Imaging. 2018;11:1419-1429. doi: 10.1016/j.jcmg.2017.10.024